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ABSTRACT
The aim of this case report and literature review is to explore the rarely highlighted co-occurrence of malignant melanoma and Parkinson’s 
disease (PD) and to describe the devastating effects on those affected. We present a case of acute confusion and worsening shuffling gait 
in a patient with Parkinson’s disease who eventually succumbed to metastatic malignant melanoma, secondary to a primary malignant 
melanoma on the back that was treated 6 years earlier. More research is needed to better characterize the associations between these two 
conditions, and to evaluate the effectiveness of prevention strategies such as melanoma screening for adults with PD.
LEARNING POINTS
• The underlying mechanism for the co-occurrence of Parkinson’s disease (PD) and malignant melanoma remains unclear but available 
evidence suggests genetic associations and environmental factors as potential causes.
• Patients with PD may require closer dermatological surveillance, particularly those with other risk factors for melanoma such as 
prolonged sun exposure.
• More research is needed to better characterize the associations between PD and skin cancers, and to evaluate the effectiveness of 




The aim of this case report and literature review is to explore the rarely highlighted co-occurrence of malignant melanoma and Parkinson’s 
disease (PD). Several large epidemiological studies have established a link between the two conditions despite the fact that they seem to 
have nothing in common. PD is a neurodegenerative disease in which loss of dopaminergic neurons results in asymmetric motor symptoms, 
namely bradykinesia, rigidity and tremors, while melanoma is a malignant transformation of melanocytes in the skin and other organs. The 
lifetime risk of being diagnosed with PD in the United Kingdom is expected to increase by 23.9% (from 2.7% in 2015) by 2025. Malignant 
melanoma is the fifth most common cancer in the United Kingdom and accounts for 4% of all new cancer cases. Individually, both conditions 
can have a significant effect on those affected, but the co-occurrence of both diseases rapidly increases morbidity and mortality as evidenced 
by the case presented. Exploring this association allows us to consider potential implications such as the possibility of melanoma screening 
for patients with PD.
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CASE DESCRIPTION 
A 77-year-old man with a 12-year history of PD was admitted to the Geriatric Ward for new onset confusion over the last 2 days and 
worsening shuffling gait. He was compliant with his medications, namely co-beneldopa 125 mg tablets six times per day, ropinirole 16 mg 
tablets once daily and citalopram 20 mg once daily. His past medical history was significant for several dermatological malignancies with the 
following histopathological diagnoses:
• 2012: Nodular basal cell carcinoma on the right neck.
• 2013: Invasive nodular malignant melanoma on the right lower back. Clark’s level 4 with a Breslow thickness of 4.8 mm. No 
lymphovascular invasion was seen. It was surgically excised and there was no lymphadenopathy at presentation and no clinical evidence 
of persisting malignancy in the surgical scar.
• 2014: Basal cell carcinoma on the right lower back.
• 2015: Lentigo maligna on the right ear lobe, a benign squamous lesion on the right lower leg, and invasive squamous cell cancer of the 
left leg.
The patient did not have a significant smoking or alcohol history, but he was retired from a job with a great deal of sun exposure. Most of his 
examination findings were normal, but significant neurological examination findings included a left homonymous hemianopia and features 
of Parkinsonism more pronounced in the right upper and lower limbs in keeping with PD. There was no associated weakness or sensory loss. 
On presentation he scored 8/10 on the Abbreviated Mental Test but his confusion progressively worsened with fewer lucid intervals. By the 
time he was discharged he no longer had the capacity to make decisions regarding his care. 
Investigations
The patient’s blood results were normal except for a normocytic normochromic anaemia.
Computed tomography (CT) of the head demonstrated multiple enhancing brain lesions, likely metastatic deposits with an acute right 
occipital intracranial-axial haematoma (Fig. 1). Magnetic resonance imaging (MRI) of the head revealed in greater detail multiple lesions 
in both cerebral hemispheres and in the cerebellar vermis in keeping with melanoma deposits (Figs. 2 and 3). CT of the thorax, abdomen 
and pelvis revealed lung metastases and extensive bilateral calcified pleural plaques (Fig. 4). No intra-abdominal malignancy or destructive 
bony lesions were identified. Given his history of malignant melanoma and the investigation findings, the patient was diagnosed as having 
metastatic malignant melanoma.
Figure 1. Non-contrast computed tomography (CT) of the head demonstrating 
multiple enhancing brain lesions, likely metastatic deposits with an acute right 
occipital intra-axial haematoma
Figure 2. Magnetic resonance imaging of the head 
demonstrating high density lesions in keeping with 
melanoma deposits, with surrounding oedematous 
changes particularly in the right frontal and occipital 
lobes 
Figure 3. Magnetic resonance imaging of the head 
demonstrating high density lesions in keeping with 
melanoma deposits
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Outcome
The Skin Multidisciplinary Team meeting concluded that best supportive care was the ideal management for him, and he was discharged to 
a care home for palliation. His neurological deterioration progressed, and he died a few months later.
DISCUSSION
PD and cancer in theory are polar opposites when it comes to their pathophysiology as one involves cellular degeneration and the other 
uncontrolled cellular proliferation, as one review article aptly puts it[1]. Therefore, it is not unreasonable to postulate that where one exists 
there should be a low risk for the other. Many epidemiological studies do in fact support this theory where PD patients have a decreased 
risk of developing lung, bladder and colorectal cancers. However, several studies have revealed a significant association between PD and 
malignant melanoma (Table 1). One study concluded that there was a seven-fold increase in the risk of developing any type of melanoma 
in patients with PD[1]. Additionally, a retrospective cohort study published by the Mayo Clinic in 2017 revealed that on average patients 
with PD were diagnosed with melanoma 7 years earlier than patients without PD[2]. Interestingly, the reverse is also true, where melanoma 
patients were found to have a 50% increased risk of developing PD[1]. The findings linking PD and melanoma are so consistent that one study 
commented that this association could not be easily explained away by improved medical surveillance of these patients[2].
While the root cause of this association remains unclear, several genes have been implicated in the pathogenesis of both melanomas and 
PD, namely:
• Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin: The LRRK2 mutation associated with PD is in the same structural position 
as the B-raf kinase mutation that is responsible for a significant portion of malignant melanomas[1].
• DJ-1: This is an established oncogene which has been found in melanomas and its mutated form was linked to early-onset familial PD[1].
• SNCA (Alpha synuclein): This gene has a pathological role in PD. Its accumulation within the central nervous system is associated with 
neurotoxicity, but it also has increased expression in melanoma cells. Its presence in both PD and melanoma provides a convincing 
argument that it may very well be a key instigator in the concurrence of both conditions[1]. 
Environmental factors such as exposure to pesticides that affect the mitochondrial electron transfer pathway (paraquat, maneb and 
rotenone) have also been linked to PD. The risk is found to be increased in those with more than 10–20 years of exposure[3].
CONCLUSION
The literature shows that there is a statistically significant association between PD and melanoma, although the root cause remains unclear. 
More research is needed to better characterize the associations between PD and melanoma, and to evaluate the effectiveness of prevention 
strategies such as melanoma screening for adults with PD.
Figure 4. Computed Tomography (CT) scan of the thorax demonstrating a metastatic lesion in the right lung
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Study type Authors Location Number of participants 95% Confidence Interval
Malignant Melanoma before Parkinson’s Disease
Case-control Olsen et al. [4] Denmark 8,090 1.03–2.01
Cohort Wirdefeldt et al. [5] Sweden 11,786 1.23–1.91
Retrospective cohort Dalvin et al. [2] USA 1,544 2–8.8
Malignant Melanoma after Parkinson’s Disease
Cohort Wirdefeldt et al. [5] Sweden 11,786 1.01–2.10
Retrospective cohort Dalvin et al. [2] USA 974 2.1–6.8
Cohort Rugbjerg et al. [6] Denmark 20,343 1.09–1.80
Prospective cohort Bertoni et al. [7] USA 1,692 1.24–4.17
Table 1. Epidemiological studies demonstrating statistically significant associations between malignant melanoma and Parkinson’s disease using 
confidence intervals
